BioSpace News Archive

Business

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer.

August 12, 2022
·
30 min read
Blood Transfusion Diagnostics Market: Rise in Demand for Blood and Blood Components Transfusions to Drive the Market

Wilmington, Delaware, United States, Transparency Market Research Inc. – Blood transfusion diagnostics are products used to conduct tests before transfusion of blood and blood products from donor to recipient.

August 12, 2022
·
9 min read
Disposable Medical Device Sensors Market is Driven by Rise in Medical Screening and Diagnostic Applications

Wilmington, Delaware, United States, Transparency Market Research Inc. – Advancements in sensor technologies and increasing trend of integration of those with medical devices have driven the evolution of the disposable medical device sensors market.

August 12, 2022
·
6 min read
Wearable Injectors Market: Rising Incidence of Chronic Diseases to Propel Market Demand

Wilmington, Delaware, United States, Transparency Market Research Inc. – A report by Transparency Market Research throws light on the key dynamics operating within the global market for wearable injectors.

August 12, 2022
·
5 min read
Rapid Microbiology Testing Market Analysis, 2031 | Drivers | Restraints | Challenges | Upcoming Growth Opportunities

The rising cases of infectious diseases and various types of chronic diseases such as cancer are projected to add boost to the overall rapid microbiology testing market.

August 12, 2022
·
6 min read
Genetown

Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock

Cerevel Therapeutics Holdings, Inc. announced the pricing of its previously announced private offering of $300.0 million aggregate principal amount of 2.50% convertible senior notes due 2027 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

August 12, 2022
·
9 min read
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) accepted a supplemental New Drug Application (sNDA) for Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of patients with relapsed or refractory Marginal Zone Lymphoma.

August 12, 2022
·
4 min read
Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

Alvotech announced that its Board of Directors has approved a plan to move its share listing from the First North Growth Market to the Nasdaq Main Market in Iceland.

August 12, 2022
·
10 min read
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

Chemomab Therapeutics, Ltd. announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development.

August 12, 2022
·
7 min read
Drug Development

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

Aptinyx Inc. today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.

August 12, 2022
·
5 min read